These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 28984155)

  • 1. Cancer-directed therapy and potential impact on survivals in nonresected hepatocellular carcinoma: SEER-Medicare population study.
    Kokabi N; Duszak R; Xing M; Howard DH; Applegate KE; Camacho JC; Kim HS
    Future Oncol; 2017 Oct; 13(23):2021-2033. PubMed ID: 28984155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study.
    El-Serag HB; Siegel AB; Davila JA; Shaib YH; Cayton-Woody M; McBride R; McGlynn KA
    J Hepatol; 2006 Jan; 44(1):158-66. PubMed ID: 16290309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sociodemographic impact on survival in unresectable hepatocellular carcinoma: a survival epidemiology and end results study.
    Kokabi N; Xing M; Duszak R; Duszak R; Howard DH; Applegate KE; Camacho JC; Kim HS
    Future Oncol; 2016 Jan; 12(2):183-98. PubMed ID: 26690268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival in unresectable AJCC stage I and II HCC and the effect of DEB-TACE: SEER versus tertiary cancer center cohort study.
    Xing M; Kokabi N; Prajapati HJ; Close O; Ludwig JM; Kim HS
    J Comp Eff Res; 2016 Mar; 5(2):141-54. PubMed ID: 26946950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A SEER Database Analysis of the Survival Advantage of Transarterial Chemoembolization for Hepatocellular Carcinoma: An Underutilized Therapy.
    Gray SH; White JA; Li P; Kilgore ML; Redden DT; Abdel Aal AK; Simpson HN; McGuire B; Eckhoff DE; Dubay DA
    J Vasc Interv Radiol; 2017 Feb; 28(2):231-237.e2. PubMed ID: 27939085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Underutilization of therapy for hepatocellular carcinoma in the medicare population.
    Shah SA; Smith JK; Li Y; Ng SC; Carroll JE; Tseng JF
    Cancer; 2011 Mar; 117(5):1019-26. PubMed ID: 20945363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare.
    Zhang X; El-Serag HB; Thrift AP
    Cancer Causes Control; 2021 Apr; 32(4):317-325. PubMed ID: 33394207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival.
    Stuart KE; Anand AJ; Jenkins RL
    Cancer; 1996 Jun; 77(11):2217-22. PubMed ID: 8635087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.
    Shaya FT; Breunig IM; Seal B; Mullins CD; Chirikov VV; Hanna N
    Pharmacoeconomics; 2014 Jan; 32(1):63-74. PubMed ID: 24293197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with Hepatocellular Carcinoma (HCC): A Surveillance, Epidemiology, End Results (SEER) analysis.
    Kamarajah SK; Frankel TL; Sonnenday C; Cho CS; Nathan H
    J Surg Oncol; 2018 Mar; 117(4):644-650. PubMed ID: 29127719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early stage hepatocellular carcinoma in the elderly: A SEER database analysis.
    Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A; Abdel-Rahman O
    J Geriatr Oncol; 2017 Jul; 8(4):277-283. PubMed ID: 28389117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Locoregional therapies for hepatocellular carcinoma: which patients are most likely to gain a survival advantage?
    Mahady SE; Charlton B; Fitzgerald P; Koorey DJ; Perry JF; Waugh RC; McCaughan GW; Strasser SI
    J Gastroenterol Hepatol; 2010 Jul; 25(7):1299-305. PubMed ID: 20594260
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma.
    Lance C; McLennan G; Obuchowski N; Cheah G; Levitin A; Sands M; Spain J; Srinivas S; Shrikanthan S; Aucejo FN; Kim R; Menon KV
    J Vasc Interv Radiol; 2011 Dec; 22(12):1697-705. PubMed ID: 21983055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of long-term survival in hepatocellular carcinomas: A longitudinal follow-up of 108 patients with small tumors.
    Chang HC; Lin YM; Yen AM; Chen SL; Wu WY; Chiu SY; Fann JC; Lin YS; Chen HH; Liao CS
    Anticancer Res; 2013 Nov; 33(11):5171-8. PubMed ID: 24222166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in epidemiology, treatment, and survival of hepatocellular carcinoma patients between 1998 and 2009: an analysis of 1066 cases of a German HCC Registry.
    Weinmann A; Koch S; Niederle IM; Schulze-Bergkamen H; König J; Hoppe-Lotichius M; Hansen T; Pitton MB; Düber C; Otto G; Schuchmann M; Galle PR; Wörns MA
    J Clin Gastroenterol; 2014 Mar; 48(3):279-89. PubMed ID: 24045276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Barcelona Clinic Liver Cancer staging system and survival of untreated hepatocellular carcinoma in a hepatitis B virus endemic area.
    Lee JH; Kim HY; Kim YJ; Yoon JH; Chung JW; Lee HS
    J Gastroenterol Hepatol; 2015 Apr; 30(4):696-705. PubMed ID: 25250761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma.
    Mathur AK; Osborne NH; Lynch RJ; Ghaferi AA; Dimick JB; Sonnenday CJ
    Arch Surg; 2010 Dec; 145(12):1158-63. PubMed ID: 21173289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.